5:36 PM
 | 
May 06, 2016
 |  BC Extra  |  Company News

Newco Vitaeris licenses Alder's clazakizumab

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) granted newco Vitaeris Inc. (Vancouver, B.C.) exclusive, worldwide rights to anti-IL-6 mAb clazakizumab (formerly ALD518). Alder helped co-found Vitaeris to house clazakizumab, which the newco intends to develop for chronic inflammatory diseases.

Vitaeris has raised $7 million in a seed round from a syndicate including HBM Healthcare Investments, family offices including Robinson...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >